AVE Secures US & EU Patent Allowances for CBD Soft-Gel
Filed with ASX · · 3 pages · English
• Patent applications allowed in the US and Europe covering Avecho’s proprietary CBD TPM® soft-gel capsule, currently in Phase III clinical development for insomnia. • Coverage extends to formulations incorporating cannabinoids beyond CBD, supporting future noncore commercialisation opportunities. • Grant of patents on the allowed applications expected by the end of FY26. • Once granted, patents w
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- September 2025 Quarterly Activities Report & Appendix 4C
- Avecho raises $2.5m via placement
- Appendix 4D and Half-year Financial Report
- Sleep Health Week: Researchers Recruiting Now for CBD Insomnia Trial
- June 2025 Quarterly Activities Report & Appendix 4C
Later from Avecho Biotechnology
- Phase III CBD Clinical Trial Recruitment Update
- December 2025 Quarterly Activities Report & Appendix 4C
- Annual Report 31 December 2025
- Avecho completes recruitment for Phase III interim analysis
- March 2026 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology